Welcome to the latest edition of our weekly EuroBiotech Report. We start this week in the U.K., where Novartis revealed it is moving its headquarters to London's White City Place, and Vectura stopped work on its nebulized formulation of budesonide following a phase 3 failure.
Elsewhere, Hookipa Pharma has teamed up with DarwinHealth to identify shared self-antigens for multiple tumor subtypes. The CEO of the U.K. drug regulator revealed he will step down next year. Stallergenes Greer’s treatment for house dust mite-induced allergic rhinitis cleared a phase 3 test. And more. — Nick Taylor
1. Novartis to move U.K. headquarters to London’s White City
Novartis is set to move its U.K. headquarters into London. The relocation will see Novartis set up in the White City Place development next to Imperial College London’s new campus.
2. Vectura cans VR475 after it fails phase 3 asthma test
A phase 3 trial of Vectura’s VR475 in patients with severe uncontrolled asthma has missed its primary endpoint. The blow prompted Vectura to halt work on the nebulized formulation of budesonide.
3. Hookipa tasks DarwinHealth with finding shared tumor antigens
Hookipa Pharma has teamed up with DarwinHealth to identify shared self-antigens for multiple tumor subtypes. The collaboration is expected to yield antigens with validated immunogenicity that Hookipa can use as the basis for immunotherapies.
4. CEO of MHRA set to leave agency in wake of Brexit
The CEO of the Medicines and Healthcare products Regulatory Agency is set to leave the agency in 10 months. Ian Hudson’s decision means the agency faces the prospect of changing leaders while dealing with the fallout from Brexit.
5. Stallergenes' allergy immunotherapy hits goal in phase 3
A phase 3 trial of Stallergenes Greer’s treatment for house dust mite-induced allergic rhinitis has met its primary endpoint. The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.
And more articles of note>>